Atsuko Murashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Atsuko Murashima has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Akio Morinobu
Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
6 shared publications - Eiichi Tanaka
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
6 shared publications - Hiromu Ito
Department of Orthopaedics, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
6 shared publications - Keiichiro Nishida
Locomotive Pain Center, Faculty of Medical Development Field, Okayama University, Okayama, Japan
6 shared publications - Masaaki Mori
Joint Research Department of Lifelong Immunotherapy, Institute of Science Tokyo , Tokyo
6 shared publications - Masataka Kohno
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
6 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (23) , e49103
Live attenuated varicella vaccines in patients treated with tumor necrosis factor-alpha inhibitors: A clinical trial
Background: Live vaccines are generally contraindicated in patients treated with biological agents. However, they are often needed in this patient population. This prospective study aimed to evaluate the immunogenicity and safety of the live attenuated varicella vaccine in patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors. Methods: This single-center, prospective study was conducted at the National Center for Child Health and Development and registered with the Japan Registry of Clinical Trials in accordance with the Japanese Clinical Trials Act. Patients receiving TNF-α inhibitors were enrolled. Those with varicella-specific immunoglobulin G (IgG) levels Export
- 5 June 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (23) , e49103
Open AccessLive attenuated varicella vaccines in patients treated with tumor necrosis factor-alpha inhibitors: A clinical trial
Background: Live vaccines are generally contraindicated in patients treated with biological agents. However, they are often needed in this patient population. This prospective study aimed to evaluate the immunogenicity and safety of the live attenuated varicella vaccine in patients receiving tumor necrosis factor-alpha (TNF-α) inhibitors. Methods: This single-center, prospective study was conducted at the National Center for Child Health and Development and registered with the Japan Registry of Clinical Trials in accordance with the Japanese Clinical Trials Act. Patients receiving TNF-α inhibitors were enrolled. Those with varicella-specific immunoglobulin G (IgG) levels Export
- Open Access
- 25 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70602
Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan
This study investigated how Japanese physicians make decisions about prescribing medications during pregnancy, based on safety information provided in drug package inserts. An online questionnaire survey targeted physicians working at pregnancy hub hospitals with expertise in drug treatment during pregnancy and physicians in general hospitals without such specialization. The findings revealed significant differences in prescribing behavior and perceptions of safety. Physicians at hub hospitals were more likely to view certain medications as safe for pregnant individuals when supported by epidemiological data, even if such drugs were contraindicated based on preclinical studies. In contrast, physicians in general hospitals followed the wording in the package inserts more strictly and often avoided prescribing. Physicians from both groups strongly needed more detailed descriptions of therapeutic benefits and epidemiological evidence in the pregnancy sections of package inserts. The results suggest that current drug labeling in Japan does not provide sufficient information for evidence‐based risk–benefit decision‐making in pregnancy care. Differences in prescribing behavior were attributed to disparities in training and access to specialized information. The study highlights the importance of revising Japanese package inserts to include more precise descriptions of clinical benefit and human data to improve the quality of medication decision‐making during pregnancy and reduce unnecessary contraindications. Improved access to training and updated information may help close the gap between general and specialized physicians and promote more consistent and appropriate care for pregnant individuals across healthcare settings.
- 25 May 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70602
Open AccessPhysicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan
This study investigated how Japanese physicians make decisions about prescribing medications during pregnancy, based on safety information provided in drug package inserts. An online questionnaire survey targeted physicians working at pregnancy hub hospitals with expertise in drug treatment during pregnancy and physicians in general hospitals without such specialization. The findings revealed significant differences in prescribing behavior and perceptions of safety. Physicians at hub hospitals were more likely to view certain medications as safe for pregnant individuals when supported by epidemiological data, even if such drugs were contraindicated based on preclinical studies. In contrast, physicians in general hospitals followed the wording in the package inserts more strictly and often avoided prescribing. Physicians from both groups strongly needed more detailed descriptions of therapeutic benefits and epidemiological evidence in the pregnancy sections of package inserts. The results suggest that current drug labeling in Japan does not provide sufficient information for evidence‐based risk–benefit decision‐making in pregnancy care. Differences in prescribing behavior were attributed to disparities in training and access to specialized information. The study highlights the importance of revising Japanese package inserts to include more precise descriptions of clinical benefit and human data to improve the quality of medication decision‐making during pregnancy and reduce unnecessary contraindications. Improved access to training and updated information may help close the gap between general and specialized physicians and promote more consistent and appropriate care for pregnant individuals across healthcare settings.
- 9 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (11) , 3857-3862
Maternal Mosapride Citrate Hydrate Exposure During the First Trimester: Assessing Risks for Congenital Anomalies
Background and Objective Data on mosapride citrate hydrate (mosapride) safety during pregnancy are limited. This study aimed to evaluate the effects of maternal mosapride exposure on pregnancy and infant outcomes. Methods We conducted a prospective cohort study using data from two teratology information centers in Japan. Pregnant women who consulted these centers between April 1988 and December 2017 were included. The incidence of major congenital anomalies was compared between women exposed to mosapride during the first trimester and a control group. Multivariate logistic regression analysis was performed to assess potential risks. Results Major congenital anomalies were observed in 2 of 104 infants (1.92%) in the mosapride group and 32 of 1693 infants (1.89%) in the control group. The relative risk was 1.02 (95% confidence interval [CI] 0.24–4.26), indicating no statistically significant difference. Other pregnancy outcomes, including stillbirth, spontaneous abortion, preterm birth, and low birth weight, also showed no significant differences between groups. Conclusion Although our study may not exclude small increases in risk due to sample size limitations, the findings suggest that mosapride exposure during early pregnancy is not associated with a substantial increase in the risk of major congenital anomalies. These findings may help alleviate concerns related to mosapride use during pregnancy.
- 9 July 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (11) , 3857-3862
Maternal Mosapride Citrate Hydrate Exposure During the First Trimester: Assessing Risks for Congenital Anomalies
Background and Objective Data on mosapride citrate hydrate (mosapride) safety during pregnancy are limited. This study aimed to evaluate the effects of maternal mosapride exposure on pregnancy and infant outcomes. Methods We conducted a prospective cohort study using data from two teratology information centers in Japan. Pregnant women who consulted these centers between April 1988 and December 2017 were included. The incidence of major congenital anomalies was compared between women exposed to mosapride during the first trimester and a control group. Multivariate logistic regression analysis was performed to assess potential risks. Results Major congenital anomalies were observed in 2 of 104 infants (1.92%) in the mosapride group and 32 of 1693 infants (1.89%) in the control group. The relative risk was 1.02 (95% confidence interval [CI] 0.24–4.26), indicating no statistically significant difference. Other pregnancy outcomes, including stillbirth, spontaneous abortion, preterm birth, and low birth weight, also showed no significant differences between groups. Conclusion Although our study may not exclude small increases in risk due to sample size limitations, the findings suggest that mosapride exposure during early pregnancy is not associated with a substantial increase in the risk of major congenital anomalies. These findings may help alleviate concerns related to mosapride use during pregnancy.
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- 7 July 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology Case Reports
- Vol. 9 (2)
Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy
The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.
- Open Access
- 15 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70048
Pharmacovigilance Pregnancy Data in a Population of Japanese Patients With Chronic Inflammatory Disease Exposed to Certolizumab Pegol
Aim: Uncontrolled chronic inflammatory diseases (CIDs) before, during, and after pregnancy, as well as some CID medications, can increase the risk of impaired fertility in addition to adverse maternal/pregnancy outcomes in women of childbearing age. We report pregnancy outcomes from prospectively reported pregnancies in Japanese women treated with certolizumab pegol (CZP). Methods: Data from July 2001 to November 2020 on CZP‐exposed pregnancies from the CZP Pharmacovigilance safety database were reviewed. Pregnancy outcomes analyzed included live birth, ectopic pregnancy, abortion (miscarriage or medically indicated/elective), and stillbirth. Congenital anomalies (major and minor), preterm delivery, and low birth weight were also examined. Results: Among 149 prospective pregnancies with maternal CZP exposure and known outcomes identified in Japanese women, 111/149 (74.5%) involved at least first‐trimester exposure and 53/149 (35.6%) were exposed in all trimesters; 135/149 (90.6%) live births, 12/149 (8.1%) abortions (11 miscarriages, one elective termination), 2/149 (1.3%) stillbirths, no ectopic pregnancies reported. One (0.7%) infant, whose mother had first‐trimester exposure, manifested a minor congenital anomaly (accessory auricle). There were no major congenital anomalies. Among live births, 3/135 (2.2%) were preterm and 10/135 (7.4%) had low birth weight. Conclusion: The safety profile of CZP in pregnant Japanese women was consistent with published global data.
- 15 January 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (1) , e70048
Open AccessPharmacovigilance Pregnancy Data in a Population of Japanese Patients With Chronic Inflammatory Disease Exposed to Certolizumab Pegol
Aim: Uncontrolled chronic inflammatory diseases (CIDs) before, during, and after pregnancy, as well as some CID medications, can increase the risk of impaired fertility in addition to adverse maternal/pregnancy outcomes in women of childbearing age. We report pregnancy outcomes from prospectively reported pregnancies in Japanese women treated with certolizumab pegol (CZP). Methods: Data from July 2001 to November 2020 on CZP‐exposed pregnancies from the CZP Pharmacovigilance safety database were reviewed. Pregnancy outcomes analyzed included live birth, ectopic pregnancy, abortion (miscarriage or medically indicated/elective), and stillbirth. Congenital anomalies (major and minor), preterm delivery, and low birth weight were also examined. Results: Among 149 prospective pregnancies with maternal CZP exposure and known outcomes identified in Japanese women, 111/149 (74.5%) involved at least first‐trimester exposure and 53/149 (35.6%) were exposed in all trimesters; 135/149 (90.6%) live births, 12/149 (8.1%) abortions (11 miscarriages, one elective termination), 2/149 (1.3%) stillbirths, no ectopic pregnancies reported. One (0.7%) infant, whose mother had first‐trimester exposure, manifested a minor congenital anomaly (accessory auricle). There were no major congenital anomalies. Among live births, 3/135 (2.2%) were preterm and 10/135 (7.4%) had low birth weight. Conclusion: The safety profile of CZP in pregnant Japanese women was consistent with published global data.
- Open Access
- 8 May 2023
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 19 (6) , 655-669
The management of women of childbearing age with rheumatoid arthritis: an expert report
The introduction of biologic therapies and a treat-to-target approach has transformed the management of rheumatoid arthritis (RA), which has led to improved outcomes for women with RA who wish to b...
- 8 May 2023
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 19 (6) , 655-669
Open AccessThe management of women of childbearing age with rheumatoid arthritis: an expert report
The introduction of biologic therapies and a treat-to-target approach has transformed the management of rheumatoid arthritis (RA), which has led to improved outcomes for women with RA who wish to b...
- 9 April 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (6) , 528-530
Diazoxide during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum: a case report
Safety information on diazoxide for pregnant and lactating women with hypoglycemia is limited. In this case report, we assessed diazoxide concentrations in maternal and infant blood, cord blood, and breast milk. We described a 30-year-old pregnant woman diagnosed with hypoglycemia due to nesidioblastosis at 4 months of age. Before becoming pregnant, she was treated with oral diazoxide (75–375 mg). All medications were discontinued after she was discovered to be pregnant. During gestational week 25, diazoxide treatment was resumed at 150–175 mg daily for repeated hypoglycemic episodes. Diazoxide administration was continued in combination with diet treatment until delivery. Glucose levels were well controlled. During gestational week 40, a male infant weighing 3069 g was delivered via spontaneous vaginal delivery with no pregnancy or neonatal complications. Diazoxide concentrations detected in maternal serum at 2.5–11.6 h after oral treatment ranged from 12.4 to 32.7 µg/mL. In cord blood, the diazoxide concentration was 18.5 µg/mL at 7.2 h after the last dose. During lactation, no hypoglycemia or hyperglycemia was observed. The approximate calculated ratio of diazoxide in breast milk and maternal serum was 0.09. The calculated daily infant dose was 0.47 mg/kg/day. The relative infant dose via breast milk ranged from 3.1% to 5.9%. Diazoxide transferred from maternal blood to the fetus across the placenta. It also transferred into breast milk, but there were no harmful effects on the infant.
- 9 April 2022
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 38 (6) , 528-530
Diazoxide during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum: a case report
Safety information on diazoxide for pregnant and lactating women with hypoglycemia is limited. In this case report, we assessed diazoxide concentrations in maternal and infant blood, cord blood, and breast milk. We described a 30-year-old pregnant woman diagnosed with hypoglycemia due to nesidioblastosis at 4 months of age. Before becoming pregnant, she was treated with oral diazoxide (75–375 mg). All medications were discontinued after she was discovered to be pregnant. During gestational week 25, diazoxide treatment was resumed at 150–175 mg daily for repeated hypoglycemic episodes. Diazoxide administration was continued in combination with diet treatment until delivery. Glucose levels were well controlled. During gestational week 40, a male infant weighing 3069 g was delivered via spontaneous vaginal delivery with no pregnancy or neonatal complications. Diazoxide concentrations detected in maternal serum at 2.5–11.6 h after oral treatment ranged from 12.4 to 32.7 µg/mL. In cord blood, the diazoxide concentration was 18.5 µg/mL at 7.2 h after the last dose. During lactation, no hypoglycemia or hyperglycemia was observed. The approximate calculated ratio of diazoxide in breast milk and maternal serum was 0.09. The calculated daily infant dose was 0.47 mg/kg/day. The relative infant dose via breast milk ranged from 3.1% to 5.9%. Diazoxide transferred from maternal blood to the fetus across the placenta. It also transferred into breast milk, but there were no harmful effects on the infant.
- Top Cited PapersOpen Access
- 16 March 2022
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 33 (1) , 21-35
Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication
Objective: The aim of this study was to update the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for RA) according to recent changes in the medical environment in Japan. This article is a digest version of the guidance.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation method to update the 2014 JCR CPG for RA. A consensus was formed by CPG panel members.Results: We identified 36 important clinical questions regarding drug treatment and developed corresponding recommendations for RA. The recommendations included the following RA medications: non-steroidal anti-inflammatory drugs, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, anti-receptor activator for nuclear factor-κB ligand antibodies, and Janus kinase inhibitors, as well as the tapering and discontinuation of these medications. Recommendations regarding the efficacy and safety of treatments in the elderly and patients with comorbidities were also developed. Finally, we used these recommendations to create an original algorithm for drug treatment for RA based on the Treat-to-Target approach.Conclusion: The 2020 JCR CPG for RA provides a useful tool for rheumatologists, health care professionals, and patients with RA, enabling shared decision-making in a variety of clinical situations.
- 16 March 2022
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 33 (1) , 21-35
Top Cited PapersOpen AccessDrug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication
Objective: The aim of this study was to update the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for RA) according to recent changes in the medical environment in Japan. This article is a digest version of the guidance.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation method to update the 2014 JCR CPG for RA. A consensus was formed by CPG panel members.Results: We identified 36 important clinical questions regarding drug treatment and developed corresponding recommendations for RA. The recommendations included the following RA medications: non-steroidal anti-inflammatory drugs, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, anti-receptor activator for nuclear factor-κB ligand antibodies, and Janus kinase inhibitors, as well as the tapering and discontinuation of these medications. Recommendations regarding the efficacy and safety of treatments in the elderly and patients with comorbidities were also developed. Finally, we used these recommendations to create an original algorithm for drug treatment for RA based on the Treat-to-Target approach.Conclusion: The 2020 JCR CPG for RA provides a useful tool for rheumatologists, health care professionals, and patients with RA, enabling shared decision-making in a variety of clinical situations.
- Open Access
- 21 February 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27 (4) , 825-826
Correction to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases
- 21 February 2022
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 27 (4) , 825-826
Open AccessCorrection to: Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases
- Open Access
- 1 September 2021
- Published by Taylor & Francis in Immunological Medicine
- Vol. 45 (2) , 79-93
Obstetric anti-phospholipid syndrome: from pathogenesis to treatment
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical manifestations such as thrombosis and obstetric complications with documented persistence of antiphospholipid antibodies (aPLs). Recent studies have revealed that the cause of aPL-related obstetric complications is dysfunction of placental trophoblasts and inflammation of the maternal–fetal interface induced by aPLs, not thrombosis. Although aPLs are associated with recurrence of serious complications during pregnancy, appropriate combination therapy with heparin and low-dose aspirin can improve the course of 70–80% of subsequent pregnancies. Preconception counseling and patient-tailored treatment are fundamental to improving maternal and fetal outcomes. Non-anticoagulant treatments such as hydroxychloroquine and statins are being developed for cases refractory to conventional treatment. Risk factors for thrombosis after pregnancy complications were identified based on the analysis of large databases of obstetric APS.
- 1 September 2021
- Published by Taylor & Francis in Immunological Medicine
- Vol. 45 (2) , 79-93
Open AccessObstetric anti-phospholipid syndrome: from pathogenesis to treatment
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by clinical manifestations such as thrombosis and obstetric complications with documented persistence of antiphospholipid antibodies (aPLs). Recent studies have revealed that the cause of aPL-related obstetric complications is dysfunction of placental trophoblasts and inflammation of the maternal–fetal interface induced by aPLs, not thrombosis. Although aPLs are associated with recurrence of serious complications during pregnancy, appropriate combination therapy with heparin and low-dose aspirin can improve the course of 70–80% of subsequent pregnancies. Preconception counseling and patient-tailored treatment are fundamental to improving maternal and fetal outcomes. Non-anticoagulant treatments such as hydroxychloroquine and statins are being developed for cases refractory to conventional treatment. Risk factors for thrombosis after pregnancy complications were identified based on the analysis of large databases of obstetric APS.